Download PDF
Thromb Haemost 2009; 101(03): 596-598
DOI: 10.1160/TH08-07-0477
Letters to the Editor
Schattauer GmbH

Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities

Maria Rita Taliani
1   Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, Università di Perugia, Perugia, Italy
,
Cecilia Becattini
1   Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, Università di Perugia, Perugia, Italy
,
Giancarlo Agnelli
1   Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, Università di Perugia, Perugia, Italy
,
Paolo Prandoni
2   Dipartimento di Scienze Mediche e Chirurgiche, Università di Padova, Padua, Italy
,
Marco Moia
3   Centro Emofilia e Trombosi, IRCCS Ospedale Maggiore, Milan
,
Mario Bazzan
4   Unità di Ematologia e Malattie Trombotiche – Cellini Humanitas, Turin, Italy
,
RosaMaria Salvi
5   U.O. Medicina d’Urgenza, Ospedale di Cattinara, Trieste, Italy
,
Walter Ageno
6   Dipartimento di Medicina Clinica, Università dell’Insubria, Varese, Italy
,
Giuliana Guazzaloca
7   Divisione di Angiologia, Policlinico Sant’ Orsola-Malpighi, Bologna, Italy
,
Davide Imberti
8   Thrombosis Center, Emergency Department, Ospedale di Piacenza, Piacenza, Italy
,
Mauro Silingardi
9   Divisione di Medicina Interna I, Arcispedale S. Maria Nuova, Reggio Emilia, Italy
,
Renzo Poggio
10   II Divisione Medicina Generale – Centro Trombosi, Ospedale Galliera, Genova, Italy
,
for the Warfarin Optimal Duration Italian Trial (WODIT) Investigators › Author Affiliations
Further Information

Publication History

Received: 29 July 2008

Accepted after major revision: 22 February 2008

Publication Date:
24 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107 (Suppl. 01) I-9-I-16.
    CrossrefPubMedGoogle Scholar
  • 2 Weitz JI, Middeldorp S, Geerts W. et al. Thrombophilia and new anticoagulant drugs. Hematology Am Soc Hematol Educ Program 2004; 1: 424-438.
    PubMedGoogle Scholar
  • 3 Van den Belt AGM, Sanson BJ, Simioni P. et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997; 157: 2227-2232.
    CrossrefPubMedGoogle Scholar
  • 4 Kearon C. Long-term management of patients after venous thromboembolism. Circulation 2004; 110 (Suppl. 01) I-10-I-18.
    CrossrefPubMedGoogle Scholar
  • 5 Ridker PM, Miletich JP, Stampfer MJ. et al. Factor V Leiden and risk of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2802.
    CrossrefPubMedGoogle Scholar
  • 6 Rintelen C, Pabinger I, Knobl P. et al. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haem 1996; 75: 229-232.
    PubMedGoogle Scholar
  • 7 Simioni P, Prandoni P, Lensing AWA. et al. The risk of recurrent venous thromboembolism in patients with an Arg 506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
    CrossrefPubMedGoogle Scholar
  • 8 Eichinger S, Pabinger I, Stumpflen A. et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77: 624-628.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Baglin C, Brown K, Luddington R. et al. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVL506Q) mutation: effect of warfarin and prediction by precipitating factors. Br J Haematol 1998; 100: 764-768.
    CrossrefPubMedGoogle Scholar
  • 10 Eichinger S, Stumpflen A, Hirschl M. et al. Hyper-homocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566-569.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 De Stefano V, Martinelli I, Mannucci PM. et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 801-806.
    CrossrefPubMedGoogle Scholar
  • 12 Lindmarker P, Schulman S, Sten-Linder M. et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999; 81: 684-689.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Kearon C, Gent M, Hirsh J. et al. A Comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907.
    CrossrefPubMedGoogle Scholar
  • 14 Meinardi JR, Middeldorp S, de Kamp PJ. et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 2002; 116: 625-631.
    CrossrefPubMedGoogle Scholar
  • 15 Baglin T, Luddington R, Brown K. et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526.
    CrossrefPubMedGoogle Scholar
  • 16 Santamaria MG, Agnelli G, Taliani MR. et al. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res 2005; 116: 301-306.
    CrossrefPubMedGoogle Scholar
  • 17 De Stefano V, Leone G, Mastrangelo S. et al. Clinical manifestations of inherited thrombophilia: a retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 72: 352-358.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Christiansen SC, Cannegieter SC, Koster T. et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. J Am Med Assoc 2005; 293: 2352-2361.
    CrossrefPubMedGoogle Scholar
  • 19 Ho WK, Hankey GJ, Quinlan DJ. et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166: 729-736.
    CrossrefPubMedGoogle Scholar
  • 20 Marchiori A, Mosena L, Prins MH. et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007; 92: 1107-1114.
    CrossrefPubMedGoogle Scholar
  • 21 Young G, Becker S, During C. et al. Influence of the factor V G1691A mutation on symptomatic recurrent venous thromboembolism (VTE) in children: an international multicenter cohort study. J Thromb Haemost. 2008 epub ahead of print.
    PubMedGoogle Scholar
  • 22 Agnelli G, Prandoni P, Santamaria MG. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345: 165-169.
    CrossrefPubMedGoogle Scholar
  • 23 Agnelli G, Prandoni P, Becattini C. et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Int Med 2003; 139: 19-25.
    CrossrefPubMedGoogle Scholar